Articles related to Hematology/Oncology

CAR T-cell therapy has changed the treatment paradigm for relapsed/refractory aggressive B-cell NHL. The approach has seen strong response rates and durable remission in those whose disease has progressed despite multiple prior treatments. This review outlines current indications for CAR T-cell therapy, major toxicities, novel CARs under investigation, CARs for various hematologic malignancies, and future directions.

Here are some highly rated but lesser-known restaurants the locals like: Less than a mile from McCormick Place is the Chinese fusion restaurant Go 4 Food. Try the Sweet and Sour Chinese-Style Ribs, the succulent Walnut Shrimp, or the spicy Chili Fusion Dungeness Crab with some Millionaire-Style Fried Rice A 10-minute drive down S. Riverside Drive yields Norman’s Bistro, featuring American creole cuisine If you are up to the 20-minute ride to Lincoln Park, the locals say Toro Sushi is the spot for sushi in Chicago Within 15 minutes of the convention center are these top-rated choices: Chicago Firehouse (American) Avec Restaurant (Mediterranean) Monteverde Restaurant & Pastificio (Italian) And if you have time before dinner, this unique museum is in the same area, just off the Magnificent Mile.

Overall, NGS-based MRD analysis in ALL seems to be especially helpful in patients with RQ-PCR+ MolNE and may help to discriminate true MRD from false positivity in this considerable and clinically important group.

In this interview, Nicole Lamanna, MD, discusses challenges and application of BTK inhibitors, results with pirtobrutinib in hematologic malignancies, specifically addressing CLL, and shares her personal observations regarding pirtobrutinib use.

Register now for the 2022 Virtual & In-Person CME Series, a multi-day, debate-driven, conference on neurotoxicity in hematologic cancers taking place from June 22-24.

Oral azactidine substantially improved survival compared with placebo irrespective of baseline MRD status, and the survival benefit with oral-AZA relative to placebo was greater in the baseline MRD+ subgroup than in the MRD− subgroup. Multivariate analysis confirmed the significant independent treatment effect of oral-AZA vs. placebo on OS and RFS when controlling for MRD status at baseline.